Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
XXB750 - NPR1 agonist
Company overview
Financial review
Conclusions
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
> Cardiovascular, Renal
and Metabolic
Immunology
Neuroscience
Oncology
Other
Global Health
Abbreviations
References
Indication
NCT05562934 (CXXB750B12201)
Hypertension
Phase
Phase 2b
Patients
170
Primary
Outcome
Change from baseline in mean 24hr ambulatory systolic blood pressure
at week 12
Measures
Arms
Intervention
Arm 1 experimental: Dose 1
Arm 2 experimental: Dose 2
Arm 3 experimental: Dose 3
Arm 4 experimental: Dose 4
Arm 5 placebo comparator
Target Patients
Resistant Hypertension Patients
Readout
Milestone(s)
2024
Publication
TBD
□ NOVARTIS Reimagining Medicine
XXB750 - NPR1 agonist
NCT06142383 (CXXB750A12201)
Indication
Phase
Heart failure
Phase 2
Change in log NT-proBNP from baseline to Week 16 [ Time Frame: Baseline to
Week 16]
Patients
720
Primary
Outcome
Measures
Arms
Intervention
Target Patients
Readout
Milestone(s)
Arm 1 Placebo Comparator
Arm 2 Experimental: XXB750 Low Dose
Arm 3 Experimental: XXB750 Medium Dose
Arm 4 Experimental: XXB750 High Dose
Arm 5 Active Comparator: Sacubitril/valsartan, open label tablet
Patients with heart failure
2026
Publication
TBD
Novartis Q4 Results | January 31, 2024
54View entire presentation